Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 70

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 70
---
.e., license of medical professionals, nursing     
 professionals, medical technology professionals, pharmaceutical professions and other applicable licenses in Thailand, Approval on      
 Opening of Medical Clinic, Approval on Opening of Pharmacy and relevant approvals to conduct IVF, embryo implant and/or transfer        
 activities issued by the Ministry of Health of Cambodia (“Cambodia MOH”) in Cambodia and licenses to carry out private                  
 medical activities (including diagnostics and treatment gynecological diseases, supervision of pregnant women before childbirth,        
 IVF in outpatient and day hospital conditions (for four (4) beds)) in Kyrgyzstan, respectively, and to ensure that such licenses        
 and registrations are in good standing on an annual basis. NewGenIvf is licensed, has licensure applications pending before appropriate 
 regulatory bodies, is exempt from licensure or registration, or is otherwise authorized under such laws in those countries in which     
 it provides its services. These licenses require it to comply with the rules and regulations of the governmental bodies that issued     
 such licenses. NewGenIvf’s failure to comply with such rules and regulations could result in criminal and/ or administrative            
 penalties, the suspension of a license, or the loss of a license, all of which could negatively impact its business. First Fertility    
 PGS had provided arrangements of accommodation without additional charges for its patients without a tourism license in Thailand,       
 all of which was subsequently ceased in early 2023. Pursuant to the Tourism Business and Guide Act 2551 (2008) of Thailand, a maximum   
 fine of THB500,000 may be imposed on First Fertility PGS as a result of the above activity without a tourism license in Thailand.       
 NewGenIvf is unable to predict, however, how its services may be viewed by regulators over time, how these laws and regulations will    
 be interpreted, or the full extent of their applicable. If a regulatory authority in any country determines that the nature of its      
 business requires that NewGenIvf be licensed under applicable laws, it may need to restructure its business or it may need to comply    
 with any related requirements, such as obtaining relevant license, paying additional regulatory fees and/or penalties for previous      
 non-compliance with relevant licensing requirements, which could adversely affect its results of operation. Additionally, in extreme    
 case, NewGenIvf may need to cease operations until it is able to obtain appropriate licensure, which may adversely affect its revenue   
 for a period of time that it cannot estimate.                                                                                           |

46

| ● | Patients’ Right Protection